NCT00955617View on ClinicalTrials.gov

DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

October 31, 2010

Conditions
Peripheral Arterial Disease
Interventions
OTHER

Contrast-enhanced MRA - Imaging examination

Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)

Trial Locations (1)

Unknown

Guerbet, Roissy CDG

Sponsors

Lead Sponsor

Guerbet
All Listed Sponsors
lead

Guerbet

INDUSTRY